Brief intro:
- Author: Minglin Chen,Yue Qi &Shusheng Gong
- Journal: Acta Oto-Laryngologica
- Doi: https://www.doi.org/10.1080/00016489.2025.2486613
- Publication Date: 2025 Apr 7
Abstract
Background: Complement C1q Like 1 (C1QL1), a secreted protein, is known to play an important role in synaptic maturation, regulation, and maintenance in central nervous system. C1QL1 is expressed in adult cochlea inner and outer hair cells. However, the mechanism of C1QL1 in cochlea remains unclear.
Objective: This study aims to reveal the mechanism of C1ql1 gene in cochlea, including its target and pathway.
Material and Methods: The protein-protein interaction analysis of C1QL1 was conducted with STRING database. The interaction between C1QL1 and BAI3 in cochlea was further confirmed by colocalization and co-immunoprecipitation. via upregulating and downregulating the expression of C1ql1, the factors in the pathway can be detected.
Results: C1QL1 protein interacts with BAI3 protein in cochlea. C1ql1 overexpression had no effect on auditory phenotype. C1ql1 regulates auditory nerve fibers growth via BAI3 and ELMO1-DOCK180-RAC1 integrin. Meanwhile, C1ql1 overexpression inhibited the expression of TIAM1-PARD3 integrin.
Conclusions and significance: C1QL1 interacts with BAI3 in cochlea and C1ql1 regulates auditory nerve fibers growth via ELMO1-DOCK180-RAC1 integrin. C1ql1 overexpression can inhibit the expression of TIAM1-PARD3 integrin."
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
